ClinicalTrials.gg
RecruitingNCT06978660CONCERTOUpdated Nov 4, 2026

Multicenter Study for the Validation of an AI-based ECG Platform for Early Cardiac Amyloidosis Diagnosis

An observational study in Transthyretin Cardiac Amyloidosis, sponsored by Idoven 1903 S.L.. Recruiting at 8 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-04.

Sponsored by Idoven 1903 S.L. · Observational

How we know

From the registry’s dates

  • Started May 2025; still recruiting 1 year 5 months later.
Updated Nov 4, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Retrospective
Enrollment
2,200
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 49 studies in Amyloidosis with a site in Spain — 14 open to participants now, 20 under way, 8 of them phase 3. Amyloidosis · Spain.

Planned enrollment
3rd of 12
2,200 · median 450
Started
2025
with 3 others
Observational
12 of 49
6 open now
Primary completion
2026-12
later than 5 of 19 live
Registered
45th of 49
by date

Among the 49 studies in Amyloidosis with a site in Spain, this one is the 3rd largest by planned enrollment of the 12 observational ones that give a count, is one of 4 that started in 2025, is one of 12 observational ones, reaches primary completion later than 5 of the 19 other live ones, and was the 45th registered.

Amyloidosis

290 studies on the registry are indexed under Amyloidosis; 92 are open to participants now.

Browse Amyloidosis studies →

Open to participants now

14 of the 49 studies in Amyloidosis with a site in Spain are open now. Recruiting first, the newest first:

8 more — sign in →

All 14 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 70 Amyloidosis studies recruiting now, 43 (61%) set no upper age limit and 3 (4%) stop at 75 or younger; 7 take children under 18; 9 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 49 studies in Amyloidosis with a site in Spain, or all of them as a file.
02

Study summary

CONCERTO is a retrospective, observational, multicentric and single-arm study to perform an external validation of the cloud-based and AI-powered electrocardiogram (ECG) analysis platform, named Willem™, to detect Transthyretin cardiac amyloidosis (ATTR-CA). Thus, this study will assess Willem™ ability to distinguish between truly diagnosed ATTR-CA patients and confirmed non-ATTR-CA patients from ECG data.

Read the detailed description

Transthyretin cardiac amyloidosis (ATTR-CA) is an infiltrative cardiomyopathy affecting cardiac health. Results from clinical trials have shown the importance of early diagnosis to improve outcomes and maximize treatment efficacy.

An electrocardiogram (ECG) is the most commonly performed cardiac diagnostic procedure, providing a large amount of information that can reflect cardiac structure and physiology. In this regard, ECG could be an ideal screening tool for ATTR-CA given its wide use, non-invasive nature, low cost and high sensitivity to reflect ATTR-CA abnormalities.

The CE-marked Willem™ ECG Analysis platform has already shown its capability to process ECG data to detect cardiac patterns and arrythmias. This retrospective, observational, multicentric and single-arm study aims to expand the capabilities of the Willem™ ECG Analysis platform, in this case to detect ATTR-CA from ECG analysis.

03

Conditions studied

  • Transthyretin Cardiac Amyloidosis

Browse trials for

Keywords

  • Transthyretin cardiac amyloidosis
  • ATTR
  • AI-based ECG Analysis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Subjects with a suspected or confirmed diagnosis of ATTR-CA

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects ≥ 18 years old
  • Subjects with 12-leads records with a 10 seconds minimum length on digital format

Exclusion criteria

Exclusion Criteria:

  • Patients with paced rhythm on the .
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Observational model
Case-control
Time perspective
Retrospective
Enrollment
2,200 participants (estimated)
Patient registry
No

Groups and cohorts

  • ATTR-CA patients

    Adult patients with confirmed diagnosis of ATTR-CA

  • Controls (non ATTR-CA subjects)

    Adult subjects suspected of ATTR-CA, but finally confirmed not to have ATTR-CA

06

What researchers measure

Primary outcomes

  1. Device performance

    Assessment of Willem ability to distinguish between confirmed diagnosed ATTR-CA patients and subjects with no ATTR-CA diagnosis from ECG data of sufficient quality. The diagnostic performance metrics will be accuracy, sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and F1-score.

    Time frame: Baseline (closest clinical assessment to ATTR-CA diagnosis)

Secondary outcomes

  1. Device performance with sub-optimal ECG data quality

    Assessment of Willem ability to distinguish between confirmed diagnosed ATTR-CA patients and subjects with no ATTR-CA diagnosis from ECG data which does not meet the minimum pre-specified quality requirements. The diagnostic performance metrics will be accuracy, sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and F1-score.

    Time frame: Baseline (closest clinical assessment to ATTR-CA diagnosis)

07

Study locations

3 of 8 sites recruiting
  • Northwestern University
    Evanston, Illinois 60208, United States
    Completed

    Not enrolling at this site.

  • Centre Hospitalier Universitaire de Toulouse
    Toulouse, 31300, France
    Recruiting
    • Olivier Lairez, MD, PhD · Contact
    • Olivier Lairez, MD, PhD · Principal investigator
  • Universitätsklinikum Bonn
    Bonn, 53127, Germany
    Completed

    Not enrolling at this site.

  • TUM Klinikum Deutsches Herzzentrum
    München, 80636, Germany
    Not yet recruiting
    • Moritz von Scheidt, MD, PhD · Contact
    • Moritz von Scheidt, MD, PhD · Principal investigator
  • Hospital Universitario Son Llàtzer
    Palma de Mallorca, Balearic Islands 07198, Spain
    Recruiting
    • Tomás Ripoll Vera, MD, PhD · Contact
    • Tomás Ripoll Vera, MD, PhD · Principal investigator
    • María Eugenia Cisneros Barroso, MD, PhD · Principal investigator
    • Ana María Far Riera, MD, PhD · Sub investigator
  • Hospital Universitario Donostia
    San Sebastián, Guipúzcoa 20014, Spain
    Completed

    Not enrolling at this site.

  • Hospital Universitario Juan Ramón Jiménez
    Huelva, Huelva 21005, Spain
    Completed

    Not enrolling at this site.

  • Queen Elizabeth University Hospital, Univeisity of Glasgow
    Glasgow, G51 4TF, United Kingdom
    Recruiting
    • David Lowe, MD, MSc · Contact
    • David Lowe, MD, MSc · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started May 2025 (actual). Primary completion is estimated for Dec 2026, 19 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 4, 2026: primary completion Sep 2026 → Dec 2026 and completion Dec 2026 → Jan 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 9, 2025
First posted
May 18, 2025
StartActual
May 27, 2025
Primary completionEst.
Dec 2026was Sep 2026
CompletionEst.
Jan 2027was Dec 2026
Last update
Nov 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Sep 30, 2026→Dec 2026
Nov 4, 2026
Study completion
Dec 31, 2026→Jan 2027
Nov 4, 2026
Show all 1 update
  1. Nov 4, 2026
    Primary completion Sep 30, 2026→Dec 2026
    Study completion Dec 31, 2026→Jan 2027

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06978660
Lead sponsor
Idoven 1903 S.L.
Collaborators
AstraZeneca
Responsible party
Sponsor
First posted
May 18, 2025
Start date
May 27, 2025
Primary completion
Dec 2026 (estimated)
Completion
Jan 2027 (estimated)
Last update
Nov 4, 2026

Study contacts

Manuel Marina-Breysse, MSc, MD
Contact
m@idoven.ai
+34618103160
José María Lillo, PhD
Contact
c@idoven.ai
Pablo García Pavía, MD, PhD
principal investigator · Hospital Universitario Puerta de Hierro

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion